All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MEB-1170
Therapeutic Area: Psychiatry/Psychology Product Name: MEB-1170
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Drug Abuse
Deal Size: $7.1 million Upfront Cash: Undisclosed
Deal Type: Funding October 29, 2020
Details:
The funds will be used to progress the company's lead candidate MEB–1170, an analgesic drug candidate for the prevention and treatment of Opioid Use Disorder, through IND filing and Phase 1 clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BXCL501
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
BXCL501 is an investigational, proprietary, orally dissolving, sublingual thin film formulation of dexmedetomidine, for the treatment of acute agitation. The Company plans to initiate a Phase 2 trial within the next several months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The potential advantage of this alternative dosage form of Quetiapine Fumarate is that it may be preferred for adult patients who experience swallowing difficulties or for adults and adolescents who have trouble swallowing tablets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT00114
Therapeutic Area: Psychiatry/Psychology Product Name: PT00114
Highest Development Status: IND Enabling Product Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 08, 2020
Details:
The capital will be used to complete the last remaining components of the Company’s investigational New Drug (IND) filing with the FDA for its lead drug compound, PT00114, known scientifically as teneurin C-terminal associated peptide (TCAP).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2020
Details:
The FDA clearance of the IND application for opioid withdrawal, is an important step in BioXcel's plans to build a neuroscience franchise around the multiple therapeutic opportunities with BXCL501.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Quetiapine Fumarate
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
Details:
This acknowledgement represents the third of several oral suspensions in neuroscience that OWP Pharmaceuticals hopes to commercialize over the next several years via a 505(b)(2) application.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
